Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Melissa Badamo
Articles by Melissa Badamo
Circular RNA Expression Linked to Disease Progression in MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 22, 2024
High circular RNA abundance is correlated with disease progression in patients with MDS.
Read More
Obe-cel Receives FDA Approval for Relapsed, Refractory B-ALL
Melissa Badamo
Acute Lymphoblastic Leukemia
|
November 21, 2024
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
Read More
Panel Discusses Imetelstat for Lower-Risk MDS Treatment
Melissa Badamo
Myelodysplastic Syndromes
|
November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
View More
FDA Approves First Menin Inhibitor for Relapsed, Refractory Acute Leukemia With KMT2A Translocation
Melissa Badamo
Acute Myeloid Leukemia
|
November 19, 2024
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
Read More
Which Patients Should Be Treated With Luspatercept?
Melissa Badamo
Myelodysplastic Syndromes
|
November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
View More
Panel Describes Dosing Considerations for Luspatercept in Lower-Risk MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
View More
Panel Discusses COMMANDS Data in Lower-Risk MDS
Melissa Badamo
Myelodysplastic Syndromes
|
November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
View More
November/December 2024
This issue of Blood Cancers Today includes a feature on MRD updates; a Get to Know with Matthew Lunning, DO, FACP; and more.
Read More
Immunotherapy Researcher Honored for 50 Years of Service at the NCI
Melissa Badamo
Print
|
November 15, 2024
Since 1974, Dr. Steven Rosenberg has served as Chief of the Surgery Branch at the NCI.
Read More
Get to Know ... Matthew Lunning, DO, FACP
Melissa Badamo
Print
|
November 22, 2024
Dr. Lunning discusses his origins in clinical research, the rise of cellular therapy, and more.
Read More
International Myeloma Society Presents Awards at 21st Annual Meeting
Melissa Badamo
Print
|
November 15, 2024
The IMS presented annual awards to three multiple myeloma clinicians and researchers during the 21st Annual Meeting.
Read More
High-Risk Patients With MM Show Favorable Outcomes After HSCT
Melissa Badamo
Myeloma
|
November 14, 2024
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Read More
Cilta-Cel Shows ‘Promising Efficacy, Safety’ in Newly Diagnosed MM
Melissa Badamo
Myeloma
|
November 14, 2024
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Read More
Daratumumab-Based Quadruplet MM Therapy Superior to Triplet Regimens
Melissa Badamo
Myeloma
|
November 14, 2024
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Read More
Isatuximab-Based Regimens Versus Standard of Care in Myeloma
Melissa Badamo
Myeloma
|
November 14, 2024
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Read More
How Do Prognostic Models Factor into Treatment Decision Making for MDS?
Melissa Badamo
Myelodysplastic Syndromes
|
November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
View More
How Is the MDS Patient Experience Measured?
Melissa Badamo
Myelodysplastic Syndromes
|
November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
View More
New Classification Effectively Stratifies Patients With AML Treated With HMAs, Venetoclax
Melissa Badamo
Acute Myeloid Leukemia
|
November 6, 2024
Researchers have validated a new molecular prognostic risk signature for patients with AML who received HMAs and venetoclax.
Read More
Pacritinib Superior to Best Available Therapy for Myelofibrosis Patients With Thrombocytopenia, Anemia
Melissa Badamo
Myelofibrosis
|
November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Read More
What Are Potential Barriers to HSCT in Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Read More
Load More